SKF-38,393

Chemical compound
| SKF-38,393
|
|---|
SKF-38,393 is a chemical compound that acts as a selective dopamine receptor agonist. It is primarily used in scientific research to study the function of dopamine receptors, particularly the D1 subtype.
Pharmacology[edit]
SKF-38,393 is known for its high affinity and selectivity for the D1 receptor over other dopamine receptor subtypes. This selectivity makes it a valuable tool in neuropharmacological research, allowing scientists to isolate and study the specific effects of D1 receptor activation.
Mechanism of Action[edit]
As a dopamine receptor agonist, SKF-38,393 mimics the action of dopamine by binding to and activating the D1 receptor. This activation leads to a cascade of intracellular events, including the activation of adenylate cyclase and the subsequent increase in cyclic AMP (cAMP) levels. These molecular events are crucial for understanding the role of D1 receptors in various physiological and pathological processes.
Research Applications[edit]
SKF-38,393 is widely used in neuroscience research to investigate the role of D1 receptors in behavior, cognition, and neuropsychiatric disorders. Studies have utilized SKF-38,393 to explore its effects on motor control, reward pathways, and memory.
Related Compounds[edit]
Other compounds related to SKF-38,393 include SKF-81,297 and SKF-82,958, which also act as selective D1 receptor agonists. These compounds are often used in conjunction with SKF-38,393 to compare and contrast their pharmacological profiles and effects.
See Also[edit]
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian